Skip to content
CompanySight
Company No. 15390647 · Incorporated 5 Jan 2024

Kodiform Therapeutics Limited

Registered name: KODIFORM THERAPEUTICS LIMITED

Part of Oxford Science Enterprises PLC group

Kodiform Therapeutics Limited does not publish its revenue or profit. Its accounts to 31 Jan 2026 show net assets of £2m and 4 employees.

Kodiform Therapeutics Limited did not publish its revenue or profit — small companies aren’t required to file a profit & loss account. Its accounts for the year to 31 Jan 2026 showed net assets of £2m and 4 employees. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 3 years of its filed accounts.

Balance sheet onlySection M · Professional, scientific and technical activitiesSIC 72110Research and experimental development on biotechnology
Status
Active
Location
London, London
Age
2 yrs · since 2024
Type
Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Jan 2026

Key figures

Small team

Revenue not disclosed

Kodiform Therapeutics Limited’s accounts for the year to 31 Jan 2026 contain a balance sheet but no profit & loss account, so its revenue and profit are not public. UK small and micro-entity companies are not required to publish a P&L — this is normal and says nothing about how the business is performing.

We never estimate revenue. Below you’ll find the balance-sheet figures that were filed — useful as indirect signals of momentum, but they are not revenue or profit.

Employees
4
Net assets
£2m

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

3 filed years

Financial history

Multi-year financials, oldest to newest
Year to4 Jan 202431 Jan 202531 Jan 2026
DisclosureNo P&LNo P&LNo P&L
Profit & loss
Revenue (turnover)———
Profit (best available)———
Employees (average)—44
Ratios
Profit margin———
Growth (year on year)
Headcount growth——0%
Balance sheet — indirect signals, not revenue
Cash at bank—£4m£1.7m
Net assets—£4.2m£2m
Fixed assets£0£136k£95.3k
Current assets—£4.1m£1.8m
Debtors—£153k£758
Deferred income—£73.3k£126k
SourceFullAccounts · bulk data Jul 2025FullAccounts · bulk data Jul 2025FullAccounts · bulk data Aug 2026
Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets
▼52%
Now £2m
Cash at bank
▼57%
Now £1.7m
Headcount
0%
Now 4
Deferred income
▲72%
Now £126k
Fixed assets
▼30%
Now £95.3k

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

  1. Oxford Science Enterprises PLCultimate parent75–100%
  2. Kodiform Therapeutics Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (17)

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Jan 2026, from the Companies House accounts bulk data published Aug 2026. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.